Actively Recruiting
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Led by Shanghai Zhongshan Hospital · Updated on 2025-04-02
49
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.
CONDITIONS
Official Title
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years, any gender
- Confirmed diagnosis of advanced biliary tract cancer by tissue or cell analysis
- Unresectable or metastatic disease with progression or intolerance to at least one prior systemic therapy, including gemcitabine-based neoadjuvant or adjuvant therapy
- At least one measurable lesion according to RECIST v1.1
- ECOG performance status of 0 or 1
- Life expectancy of 3 months or more
- Adequate laboratory and organ function during screening period
You will not qualify if you...
- Known allergy to any component of HRS-4642 or adebrelimab
- Received anti-tumor chemotherapy within 4 weeks before starting study drug, including certain small molecule targeted drugs
- Untreated or active brain metastases
- Any other condition that could affect study results or cause early study termination as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200020
Actively Recruiting
Research Team
G
Guoming Shi, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here